Oral Answers to Questions

Debate between John Penrose and Steve Barclay

Tuesday 17th October 2023 Commons Chamber

[Steve Barclay]

During the pandemic, as the hon. Lady knows, the Government prioritised the clinically extremely vulnerable and significant investment went in there. We follow the guidance from the UK Health Security Agency about the right level of infection control. More widely, we need to look at what medicine is effective. If it relates to immunosuppressants, there was a big debate in summer 2022 about that issue and we keep the science under active review.

[John Penrose (Weston-super-Mare) (Con)]

T7. I thank Ministers for their earlier helpful replies about NHS dentistry, but I am afraid the situation in Weston-super-Mare remains extremely worrying. Local residents regularly say there is not a single local dentist accepting new adult NHS patients, and many practices have actively reduced NHS work since the pandemic. I have pushed both NHS England and the local integrated care board, but all we have so far are PowerPoint presentations rather than bookable appointments. What hope can the Secretary of State offer to Westonians who have paid their taxes, but are not getting any NHS dentistry in exchange?

Oral Answers to Questions

Debate between John Penrose and Steve Barclay

Tuesday 7th March 2023 Commons Chamber

[John Penrose (Weston-super-Mare) (Con)]

T9. Finding and fixing the underlying causes of health inequalities has defeated Governments of all types for decades. Less well-off British families still live significantly shorter, sicker lives than richer families, cramping their life chances and making it harder to avoid or escape poverty. The long-expected health inequalities White Paper is essential to changing that. Does the Secretary of State expect it to be published this month? If not, will he meet me to discuss it?

[Steve Barclay]

As we heard earlier from the Parliamentary Under-Secretary of State, my hon. Friend the Member for Harborough (Neil O’Brien), the major conditions strategy report will deal with those issues. However, it is also important to consider the variation in performance between integrated care boards and how we can raise the bottom quartile to the level of the top quartile—there is far too much variation within the NHS—and to be data-driven, so that when it comes to genomics and screening we can target the outliers more precisely. That is what is behind the issue to which my hon. Friend has rightly drawn attention.